市場調查報告書

高鈣血症治療藥的全球市場 - 藥物的各類型 (雙膦酸鹽,抑鈣素,糖皮質激素,Denosumab,鈣受體激動劑)、各流通管道、各地區:市場規模、佔有率、未來展望、機會分析

Hypercalcemia Treatment Market, By Drug Type (Bisphosphonates, Calcitonin, Glucocorticoids, Denosumab, Calcimimetics), By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

出版商 Coherent Market Insights 商品編碼 927635
出版日期 內容資訊 英文 167 Pages
商品交期: 2-3個工作天內
價格
高鈣血症治療藥的全球市場 - 藥物的各類型 (雙膦酸鹽,抑鈣素,糖皮質激素,Denosumab,鈣受體激動劑)、各流通管道、各地區:市場規模、佔有率、未來展望、機會分析 Hypercalcemia Treatment Market, By Drug Type (Bisphosphonates, Calcitonin, Glucocorticoids, Denosumab, Calcimimetics), By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
出版日期: 2020年02月17日內容資訊: 英文 167 Pages
簡介

本報告提供全球量鈣血症治療藥的市場相關分析,產品概要,及市場基本結構及促進、阻礙因素,整體市場規模預測 (過去2年、今後9年份),藥物的各類型、各流通管道、各地區的詳細趨勢,主要企業的簡介、業績、策略計劃等調查。

第1章 分析目的、前提條件

第2章 市場概要

  • 分析概要
    • 市場定義和範圍
  • 摘要整理
  • COM (Coherent Opportunity Map:市場機會藍圖)

第3章 市場動態、規定、趨勢分析

  • 市場動態
    • 推動市場要素
      • 供給側面的促進因素
      • 需求方面的促進因素
      • 景氣的促進因素
    • 阻礙市場要素
    • 市場機會
    • 影響度分析
  • 近幾年主要的動向
  • 法規方案
  • 醫療費償付方案
  • 開發平台分析

第4章 全球量鈣血症治療藥市場:藥物的各類型

  • 簡介
  • 市場佔有率:各類型 (最新值、預測值)
  • 與前一年同期比較成長率 (YoY):各類型 (今後9年)
  • 各市場區隔趨勢
    • 雙膦酸鹽
      • 簡介
      • 市場規模與其預測,與前一年同期相比成長率 (YoY) (以金額為準,今後9年)
      • 各市場區隔詳細趨勢
        • Clodronate
        • Etidronate
        • Ibandronate
        • Pamidronate
        • Zoledronic Acid
    • 抑鈣素
    • 糖皮質激素
    • Denosumab
    • 鈣受體激動劑 (鈣模仿藥)

第5章 全球量鈣血症治療藥市場:各流通管道

  • 各市場區隔趨勢
    • 醫院
    • 診所
    • 獨立型藥局、藥妝店

第6章 全球量鈣血症治療藥市場:各地區

  • 各市場區隔趨勢
    • 北美
      • 美國
      • 加拿大
    • 歐洲
      • 英國
      • 德國
      • 義大利
      • 法國
      • 西班牙
      • 俄羅斯
      • 其他
    • 亞太地區
      • 中國
      • 印度
      • 日本
      • ASEAN
      • 澳洲
      • 韓國
      • 其他
    • 南美
      • 巴西
      • 墨西哥
      • 阿根廷
      • 其他
    • 中東
      • 波灣合作理事會 (GCC) 各國
      • 以色列
      • 其他
    • 非洲
      • 北非
      • 中非
      • 南非

第7章 競爭情形

  • 企業簡介
    • Bayer Pharma AG
      • 公司概要
      • 產品系列
      • 近幾年的主要趨勢
      • 財務成果
      • 策略
    • Sun Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Pfizer Inc.
    • Amgen Inc.
    • Novartis AG
    • Dr. Reddy's Laboratories Ltd.
    • Cipla Inc.
    • XOMA Corporation

第8章 附錄

目錄

Hypercalcemia is increased level of calcium in the blood which is caused majorly due to malignancy or hyperparathyroidism. Approximately 20 to 30% of cancer patients suffer from hypercalcemia. Hypercalcemia due to cancer is of four types such as humoral hypercalcemia of malignancy, osteolytic hypercalcemia, secretion of active vitamin D by some lymphomas, and ectopic parathyroid hormone (PTH) secretion which is a rare type. Treatment options of hypercalcemia include bisphosphonates, calcitonin, glucocorticoids, denosumab, and calcimimetics. Bisphosphonates are highly prescribed medicines for management of hypercalcemia.

Restraints of the Global Hypercalcemia Treatment Market

Factors such as low research and development due to clinical trials issues (difficulty in finding patients), and limited treatment options are expected to hinder growth of the market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global hypercalcemia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019-2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global hypercalcemia treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Cipla Inc., and XOMA Corporation.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global hypercalcemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Hypercalcemia Treatment Market, By Drug Type:
    • Bisphosphonates
  • Clodronate
  • Etidronate
  • Ibandronate
  • Pamidronate
  • Zoledronic Acid
    • Calcitonin
    • Glucocorticoids
    • Denosumab
    • Calcimimetics
  • Global Hypercalcemia Treatment Market, By Distribution Channel:
    • Hospitals
    • Clinics
    • Independent Pharmacy & Drug Stores
  • Global Hypercalcemia Treatment Market, By Geography:
    • North America
  • By Drug Type
    • Bisphosphonates
      • Clodronate
      • Etidronate
      • Ibandronate
      • Pamidronate
      • Zoledronic Acid
    • Calcitonin
    • Glucocorticoids
    • Denosumab
    • Calcimimetics
  • By Distribution Channel
    • Hospitals
    • Clinics
    • Independent Pharmacy & Drug Stores
  • By Country:
    • U.S.
    • Canada
    • Europe
  • By Drug Type
    • Bisphosphonates
      • Clodronate
      • Etidronate
      • Ibandronate
      • Pamidronate
      • Zoledronic Acid
    • Calcitonin
    • Glucocorticoids
    • Denosumab
    • Calcimimetics
  • By Distribution Channel
    • Hospitals
    • Clinics
    • Independent Pharmacy & Drug Stores
  • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • By Drug Type
    • Bisphosphonates
      • Clodronate
      • Etidronate
      • Ibandronate
      • Pamidronate
      • Zoledronic Acid
    • Calcitonin
    • Glucocorticoids
    • Denosumab
    • Calcimimetics
  • By Distribution Channel
    • Hospitals
    • Clinics
    • Independent Pharmacy & Drug Stores
  • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
  • By Drug Type
    • Bisphosphonates
      • Clodronate
      • Etidronate
      • Ibandronate
      • Pamidronate
      • Zoledronic Acid
    • Calcitonin
    • Glucocorticoids
    • Denosumab
    • Calcimimetics
  • By Distribution Channel
    • Hospitals
    • Clinics
    • Independent Pharmacy & Drug Stores
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East:
  • By Drug Type
    • Bisphosphonates
      • Clodronate
      • Etidronate
      • Ibandronate
      • Pamidronate
      • Zoledronic Acid
    • Calcitonin
    • Glucocorticoids
    • Denosumab
    • Calcimimetics
  • By Distribution Channel
    • Hospitals
    • Clinics
    • Independent Pharmacy & Drug Stores
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • By Drug Type
    • Bisphosphonates
      • Clodronate
      • Etidronate
      • Ibandronate
      • Pamidronate
      • Zoledronic Acid
    • Calcitonin
    • Glucocorticoids
    • Denosumab
    • Calcimimetics
  • By Distribution Channel
    • Hospitals
    • Clinics
    • Independent Pharmacy & Drug Stores
  • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
    • Bayer Pharma AG*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
    • Sun Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Pfizer Inc.
    • Amgen Inc.
    • Novartis AG
    • Dr. Reddy's Laboratories Ltd.
    • Cipla Inc.
    • XOMA Corporation

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • Reimbursement Scenario
    • Pipeline Analysis

4. Global Hypercalcemia Treatment Market, By Drug, 2019 - 2027 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017-2027
    • Segment Trends
    • Bisphosphonates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Segment Trends
    • Clodronate
    • Etidronate
    • Ibandronate
    • Pamidronate
    • Zoledronic Acid
    • Calcitonin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Segment Trends
    • Glucocorticoids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Segment Trends
    • Denosumab
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Segment Trends
    • Calcimimetics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Segment Trends

5. Global Hypercalcemia Treatment Market, By Distribution Channel, 2016 - 2027 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017-2027
    • Segment Trends
    • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Independent Pharmacy & Drug Stores
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Hypercalcemia Treatment Market, By Regions, 2016 - 2027 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017-2027
    • Segment Trends
    • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
    • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

    • Company Profiles
    • Bayer Pharma AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sun Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Dr. Reddy's Laboratories Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Cipla Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • XOMA Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact